Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Oncosec Medical (ONCS)

Oncosec Medical (ONCS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,262
  • Shares Outstanding, K 4,554
  • Annual Sales, $ 0 K
  • Annual Income, $ -34,180 K
  • 60-Month Beta 1.99
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ONCS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -15.29
  • Most Recent Earnings $-2.65 on 03/13/23
  • Latest Earnings Date 06/27/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -5.49
  • Growth Rate Est. (year over year) +18,296.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1800 +54.00%
on 06/22/23
0.5100 -45.65%
on 05/24/23
-0.2329 (-45.66%)
since 05/23/23
3-Month
0.1800 +54.00%
on 06/22/23
3.2900 -91.57%
on 03/27/23
-1.9528 (-87.57%)
since 03/23/23
52-Week
0.1800 +54.00%
on 06/22/23
20.4600 -98.65%
on 06/27/22
-18.6428 (-98.53%)
since 06/23/22

Most Recent Stories

More News
OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

/PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral...

ONCS : 0.2772 (+31.87%)
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

/PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral...

ONCS : 0.2772 (+31.87%)
OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program

/PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral...

ONCS : 0.2772 (+31.87%)
OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

/PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral...

ONCS : 0.2772 (+31.87%)
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

/PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral...

ONCS : 0.2772 (+31.87%)
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

/PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral...

ONCS : 0.2772 (+31.87%)
OncoSec Announces Pricing of $3.5 Million Public Offering

/PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing...

ONCS : 0.2772 (+31.87%)
OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma

/PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical stage biotechnology company developing intratumoral...

ONCS : 0.2772 (+31.87%)
OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

/PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral...

ONCS : 0.2772 (+31.87%)
OncoSec Announces Reverse Stock Split

/PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing...

ONCS : 0.2772 (+31.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in...

See More

Key Turning Points

3rd Resistance Point 0.5108
2nd Resistance Point 0.4540
1st Resistance Point 0.3656
Last Price 0.2772
1st Support Level 0.2204
2nd Support Level 0.1636
3rd Support Level 0.0752

See More

52-Week High 20.4600
Fibonacci 61.8% 12.7130
Fibonacci 50% 10.3200
Fibonacci 38.2% 7.9270
Last Price 0.2772
52-Week Low 0.1800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar